Primary Systemic Amyloidosis - Pipeline Review, H2 2012

Description: Primary Systemic Amyloidosis – Pipeline Review, H2 2012

Summary

Global Markets Direct's, 'Primary Systemic Amyloidosis - Pipeline Review, H2 2012', provides an overview of
the indication's therapeutic pipeline. This report provides information on the therapeutic development for
Primary Systemic Amyloidosis, complete with latest updates, and special features on late-stage and
discontinued projects. It also reviews key players involved in the therapeutic development for Primary
Systemic Amyloidosis. Primary Systemic Amyloidosis - Pipeline Review, Half Year is built using data and
information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC
filings, investor presentations and featured press releases from company/university sites and industry-
specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of
data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Primary Systemic Amyloidosis.
- A review of the Primary Systemic Amyloidosis products under development by companies and
  universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration
  stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Primary Systemic Amyloidosis pipeline on the basis of route of administration and
  molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Primary
  Systemic Amyloidosis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies
to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Primary Systemic Amyloidosis pipeline
depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the
  most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that
drove them from pipeline.

Contents:

2 List of Tables 5
List of Figures 5
Introduction 6
REPORT COVERAGE 6
Primary Systemic Amyloidosis Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Primary Systemic Amyloidosis 8
Primary Systemic Amyloidosis Therapeutics under Development by Companies 10
Primary Systemic Amyloidosis Therapeutics under Investigation by Universities/Institutes 11
Late Stage Products 13
Comparative Analysis 13
Mid Clinical Stage Products 14
Comparative Analysis 14
Early Clinical Stage Products 15
Comparative Analysis 15
Pre-Clinical Stage Products 16
Comparative Analysis 16
Primary Systemic Amyloidosis Therapeutics – Products under Development by Companies 17
Primary Systemic Amyloidosis Therapeutics – Products under Investigation by Universities/Institutes 18
Companies Involved in Primary Systemic Amyloidosis Therapeutics Development 19
Millennium Pharmaceuticals, Inc. 19
Elan Corporation, plc 20
Primary Systemic Amyloidosis – Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Combination Products 22
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
ixazomib citrate - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Lenalidomide + Dexamethasone + Cyclophosphamide - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Iododoxorubicin - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Velcade + Melphalan + Dexamethasone - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Velcade + Dexamethasone + Melphalan + Stem Cell Transplantation - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 35
Revlimid + Cyclophosphamide + Dexamethasone - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Filgrastim + Melphalan - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Filgrastim + Melphalan - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Melphalan + Lenalidomide + Dexamethasone - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Bortezomib + Cyclophosphamide + Dexamethasone - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Melphalan + Filgrastim + Autologous Hematopoietic Stem Cell Transplantation - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Dexamethasone + Melphalan + Thalidomide + Filgrastim - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Lenalidomide - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Melphalan + Autologous Stem Cell Transplantation + Bortezomib + Dexamethasone - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Filgrastim + Melphalan + Cyclophosphamide + Dexamethasone + Thalidomide + Peripheral Blood Stem Cell Transplantation - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 52
Interferon Alfa + Dexamethasone - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Melphalan + Bortezomib + Dexamethasone + Stem Cell Transplantion - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Bortezomib + Melphalan + Filgrastim + Autologous Hematopoietic Stem Cell Transplantation - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 57
Melpharan + Dexamethasone + Bortezomib - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Lendexal + Cyclophosphamide + Dexamethasone - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Filgrastim + Melphalan + Stem Cell Transplantation - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
High Dose Chemotherapy + Autologous Hematopoietic Cell Transplantation - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
NEOD-001 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Primary Systemic Amyloidosis Therapeutics – Drug Profile Updates 65
Primary Systemic Amyloidosis Therapeutics – Discontinued Products 67
Primary Systemic Amyloidosis Therapeutics - Dormant Products 68
Appendix 69
Methodology 69
Coverage 69
Secondary Research 69
Primary Research 69
Expert Panel Validation 69
Contact Us 70
Disclaimer 70

List of Tables
Number of Products Under Development for Primary Systemic Amyloidosis, H2 2012 8
Products under Development for Primary Systemic Amyloidosis – Comparative Analysis, H2 2012 9
Fax Order Form

To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information

Please verify that the product information is correct and select the format(s) you require.

<table>
<thead>
<tr>
<th>Product Name:</th>
<th>Primary Systemic Amyloidosis - Pipeline Review, H2 2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>Web Address:</td>
<td><a href="http://www.researchandmarkets.com/reports/2298909/">http://www.researchandmarkets.com/reports/2298909/</a></td>
</tr>
<tr>
<td>Office Code:</td>
<td>SCD2UV19</td>
</tr>
</tbody>
</table>

Product Formats

Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) -</td>
<td>USD 2000</td>
</tr>
<tr>
<td>Single User:</td>
<td></td>
</tr>
<tr>
<td>Electronic (PDF) -</td>
<td>USD 4000</td>
</tr>
<tr>
<td>Site License:</td>
<td></td>
</tr>
<tr>
<td>Electronic (PDF) -</td>
<td>USD 6000</td>
</tr>
<tr>
<td>Enterprisewide:</td>
<td></td>
</tr>
</tbody>
</table>

Contact Information

Please enter all the information below in BLOCK CAPITALS

<table>
<thead>
<tr>
<th>Title:</th>
<th>Mr ☐</th>
<th>Mrs ☐</th>
<th>Dr ☐</th>
<th>Miss ☐</th>
<th>Ms ☐</th>
<th>Prof ☐</th>
</tr>
</thead>
<tbody>
<tr>
<td>First Name:</td>
<td>___________________________</td>
<td>Last Name:</td>
<td>___________________________</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Email Address: *</td>
<td>____________________________________</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Job Title:</td>
<td>____________________________________</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Organisation:</td>
<td>____________________________________</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Address:</td>
<td>____________________________________</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>City:</td>
<td>____________________________________</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Postal / Zip Code:</td>
<td>____________________________________</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Country:</td>
<td>____________________________________</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phone Number:</td>
<td>____________________________________</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fax Number:</td>
<td>____________________________________</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World